Athira to Begin Open-label Extension Studies of ATH-1017

Athira to Begin Open-label Extension Studies of ATH-1017

307575

Athira to Begin Open-label Extension Studies of ATH-1017

Athira Pharma, Inc will initiate an open-label extension study for two ongoing clinical trials investigating ATH-1017 to treat Alzheimer’s disease. Both clinical trials — the Phase 2/3 LIFT-AD (NCT04488419) and Phase 2 ACT-AD (NCT04491006) — are investigating ATH-1017, a small molecule designed to enhance the effect of hepatocyte growth factor (HGF), and its receptor, MET. Both are expressed in the central nervous system. The trials are still recruiting. More information about enrolling is available here and here. HGF works on…

You must be logged in to read/download the full post.